[**Translation:** Please note that the following purports to be a translation from the Japanese original Notice of Resolution of the 112th Annual General Meeting of Shareholders for the Business Term Ended December 31, 2022 of Chugai Pharmaceutical Co., Ltd. prepared for the convenience of shareholders outside Japan with voting rights. However, in the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Securities Code: 4519)

March 30, 2023

To the Shareholders:

# NOTICE OF RESOLUTION OF THE 112th ANNUAL GENERAL MEETING OF SHAREHOLDERS

We are pleased to announce that the matters below were reported and resolved at the 112th Annual General Meeting of Shareholders of Chugai Pharmaceutical Co., Ltd. held today (the "AGM").

Yours very truly,

Osamu Okuda Representative Director, President & CEO CHUGAI PHARMACEUTICAL CO., LTD. (the "Company") 5-1 Ukima 5-chome, Kita-ku, Tokyo 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo

#### **PARTICULARS**

#### **Matters Reported:**

The Business Report for the Business Term (January 1, 2022 to December 31, 2022), Non-Consolidated Financial Statements for the Business Term, Consolidated Financial Statements for the Business Term, and the Report on the Results of Audit of the Consolidated Financial Statements by the Accounting Auditor and Audit & Supervisory Board

The contents of the above were reported.

## **Matters Resolved:**

**First Proposal** 

### **Appropriation of Surplus**

This item was approved and resolved as originally proposed. Appropriation of surplus for the end of the Term was decided to be JPY40 per share of common stock of the Company, and JPY65,800,822,760 in an aggregate amount.

#### Second Proposal

### **Election of Five (5) Directors**

This item was approved and resolved as originally proposed. Two (2) Directors, namely, Christoph Franz and James H. Sabry were reelected and assumed office as Directors. Three (3) Directors, namely, Fumio Tateishi, Hideo Teramoto and Teresa A. Graham were newly elected and assumed office as Directors.

Directors Fumio Tateishi and Hideo Teramoto are Outside Directors.

#### **Third Proposal**

## Election of Two (2) Audit & Supervisory Board Members

This item was approved and resolved as originally proposed. Two (2) Audit & Supervisory Board Members, namely, Shigehiro Yamada and Yumiko Waseda were newly elected and assumed office as Audit & Supervisory Board Member.

Audit & Supervisory Board Member Yumiko Waseda is an Outside Audit & Supervisory Board Member.

– End –

## Directors and Audit & Supervisory Board Members

Based on the resolution by the Board of Directors and the Audit & Supervisory Board which were held after the AGM, Directors and Audit & Supervisory Board Members of the Company are as follows:

Representative Director, President & CEO	Osamu Okuda	
Director, Executive Vice President	Hisafumi Yamada	
Director, Executive Vice President & CFO	Toshiaki Itagaki	
Outside Director	Mariko Y Momoi	
Outside Director	Fumio Tateishi	newly elected
Outside Director	Hideo Teramoto	newly elected
Director	Christoph Franz	reelected
Director	James H. Sabry	reelected
Director	Teresa A. Graham	newly elected
Full-time Audit & Supervisory Board Member	Yoshiaki Ohashi	
Full-time Audit & Supervisory Board Member	Shigehiro Yamada	newly elected
Outside Audit & Supervisory Board Member	Takaaki Nimura	
Outside Audit & Supervisory Board Member	Kenichi Masuda	
Outside Audit & Supervisory Board Member	Yumiko Waseda	newly elected

## Executive Officers of the Company, as of April 1, 2023, will be as follows:

Executive Vice President	Tetsuya Yamaguchi	Vice President	Junichi Nezu
Executive Vice President	Junichi Ebihara	Vice President	Tsukasa Kusano
Executive Vice President	Shinji Hidaka	Vice President	Kaori Ouchi
Executive Vice President	Yoshiyuki Yano	Vice President	Shinya Takuma
Executive Vice President	Satoko Shisai	Vice President	Hitoshi likura
Senior Vice President	lwaaki Taniguchi	Vice President	Masayoshi Higuchi
		Vice President	Norihisa Onozawa